Last reviewed · How we verify
NCT05392400
The Use of Steri3X for Prevention of Post-operative Wound Infections in Cesarean Sections
Phase 2 trial testing Steri3X in Surgical Site Infection in 1,000 participants. Status unknown.
7 February 2024
Quick facts
| Lead sponsor | University of Tennessee |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 1,000 |
| Start date | 7 February 2023 |
| Primary completion | 7 February 2024 |
| Estimated completion | 7 February 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Steri3X
- Control
Conditions studied
- Surgical Site Infection — all drugs for Surgical Site Infection →
- Cesarean Section; Complications, Wound, Infection (Following Delivery) — all drugs for Cesarean Section; Complications, Wound, Infection (Following Delivery) →
- Postpartum Complication — all drugs for Postpartum Complication →
Sponsor
University of Tennessee
Who can join
16 and older, female only, with Surgical Site Infection or Cesarean Section; Complications, Wound, Infection (Following Delivery). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Postpartum infection if a major cause of maternal morbidity and mortality and surgical site infections are some of the common complications following cesarean section. This study aims to determine the effect of Steri3X on the incidence of cesarean section SSI at Regional One Hospital.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05392400
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Surgical Site Infection
Currently open trials in the same condition.
- NCT07501897 — Investigating the Impact of Cold Atmospheric Plasma Treatment on Wound Healing at Cannulation Sites in Patients Followin · NA · recruiting
- NCT07311395 — Local Subcutaneous Gentamicin for Prevention of Surgical Site Infection After Elective Cesarean Section · NA · recruiting
- NCT06649890 — A Novel Surgical Irrigation Solution in Post-Mastectomy Reconstruction: Evaluating Xperience™ · NA · recruiting
- NCT07005635 — The Effects of Different Time Reminder On Surgical Hand Scrubing · NA · active not recruiting
- NCT07049614 — Comparative Study of Postoperative Surgical Site Infections in Diabetic and Non-Diabetic Patients · active not recruiting
Other University of Tennessee trials
Trials by the same sponsor.
- NCT07465432 — Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries · Phase 4 · recruiting
- NCT07225725 — Access to Care Pilot for ED-Presenting Head and Neck Cancer Patients (ENRICH-HNC) · NA · not yet recruiting
- NCT07227519 — Effects of UPF Warning Labels on Social Media Among Teens and Young Adults · NA · not yet recruiting
- NCT06850857 — Multi-Institutional IMPACT Validation · enrolling by invitation
- NCT06745180 — Making Healthy Habits Stick · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05392400 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Tennessee
- Last refreshed: 13 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05392400.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing